Detalhe da pesquisa
1.
Targeting acute kidney injury in COVID-19.
Nephrol Dial Transplant
; 35(10): 1652-1662, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33022712
2.
Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.
Blood
; 126(17): 1996-2004, 2015 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26330243
3.
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Blood
; 123(5): 632-9, 2014 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24335104
4.
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
Invest New Drugs
; 34(4): 439-49, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27056178
5.
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Cancer Cell
; 12(2): 131-44, 2007 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17692805
6.
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Blood
; 119(19): 4375-82, 2012 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-22422823
7.
Sequence analysis of ß-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Blood
; 120(23): 4513-6, 2012 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-23018640
8.
Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 24(1): 32-39, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37783639
9.
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.
Blood
; 116(14): 2543-53, 2010 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-20574050
10.
Genetic variation associated with bortezomib-induced peripheral neuropathy.
Pharmacogenet Genomics
; 21(3): 121-9, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21228734
11.
Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy.
Haematologica
; 96(11): 1662-9, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21791470
12.
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.
Cancer Res
; 67(7): 2982-9, 2007 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17409404
13.
Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma.
Br J Haematol
; 158(2): 290-292, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22533368
14.
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
J Clin Oncol
; 35(31): 3538-3546, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28862883
15.
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Clin Cancer Res
; 22(1): 34-43, 2016 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26561559
16.
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 22(4): 847-57, 2016 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26423795
17.
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
Cancer Cell
; 29(5): 639-652, 2016 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27132469
18.
A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.
PLoS One
; 8(6): e66361, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23840451
19.
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
Clin Cancer Res
; 19(9): 2551-61, 2013 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23549871
20.
An historic perspective of proteasome inhibition.
Semin Hematol
; 49(3): 196-206, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22726542